Cat. No.: DAB-0012106
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IP, IF |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human GUCY2C protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | GUCY2C |
| UniProt No. | P25092 |
| Gene ID | 2984 |
| Gene Description | Guanylyl cyclase C is a type I transmembrane glycoprotein whose expression in normal tissue is largely restricted to the apical membranes of polarized epithelial cells of the intestine. The guanylyl cyclase activity within the intracellular domain of GUCY2C is activated by binding exogenous bacterial enterotoxins and the endogenous peptide hormone agonists, guanylin and uroguanylin, which facilitates production of the second messenger cGMP. GUCY2C signaling plays a critical role in regulating the metabolism, proliferation, and differentiation of intestinal epithelial cells. These processes are critical for epithelial barrier renewal, water, and ion balance. Research studies have shown that the GUCY2C signaling axis functions to suppress intestinal tumorigenesis, in part, by restraining AKT activity. Lesions in the GUCY2C signaling axis that frequently contribute to cellular transformation are associated with a loss of expression of its endogenous ligands, which promotes a compensatory increase in GUCY2C expression. Indeed, GUCY2C expression is maintained in a high percentage of primary and metastatic human colorectal tumors, which has raised interest in therapeutically targeting this receptor. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
